More on ANAB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (6.5 Score)
- Holders

Upcoming Events

- Earnings (8/7/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Anaptysbio (NQ:ANAB)
Delayed: 55.41 -1.87 (3.26%)
Prev. Close $57.28  
Open$55.41 
52 Wk High$ 
52 Wk Low$ 
Day High$58.29 
Day Low$53.70 
P/E N/A  
EPS$ 
Volume492,665 

Friends, Peers and Foes (?): VNDA, TRAX, ABBV, AMGN, BMY (more...)

Mar 6, 2026 09:07 AM AnaptysBio (ANAB) PT Raised to $50 at Truist Securities on improved outlook for Jemperli
Mar 5, 2026 06:54 AM AnaptysBio (ANAB) PT Raised to $85 at Stifel After Q4 Update
Mar 4, 2026 06:41 AM AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright
Mar 4, 2026 05:48 AM Guggenheim on AnaptysBio (ANAB) Spinoff: 'Additional potential upside may be derived from imsidolimab in generalized pustular psoriasis'
Mar 4, 2026 03:10 AM AnaptysBio (ANAB) PT Raised to $79 at Barclays
Mar 3, 2026 04:38 PM AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 71c
Mar 3, 2026 04:27 PM Form 10-K ANAPTYSBIO, INC For: Dec 31
Mar 3, 2026 04:22 PM Form 8-K ANAPTYSBIO, INC For: Mar 03
Mar 3, 2026 04:15 PM Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
Feb 25, 2026 07:19 AM FDA accepts Vanda's drug application for rare skin disorder treatment
View All Articles

Entities mentioned with ANAB

View All Entities